^
Association details:
| Biomarker: | EZR-ROS1 fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) + Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case report: Successful sequential therapy of crizotinb and entrectinib in ROS1-positive non-small-cell lung cancer with brain metastasis in later-settings
Published date:
12/22/2023
Excerpt:
Next-generation sequencing (NGS) of the biopsy from neck lymph node identified EZR-ROS1 (1.25% abundance)….The patient had a total PFS of 13 months from sequential crizotinib and entrectinib therapy.
DOI:
10.1097/MD.0000000000036591
